Singapore, July 30, 2010: Hard to Treat Diseases(HTDS), a Chinese company specializing in biological Vaccines, announced the company's intention to sell current subsidiary Slavica Biochem to a US-based publicly traded biomedical company.

HTDS said it is pleased with the performance of Slavica, a Belgrade-based medical research centre that is currently evaluating various medications and clinical trials geared toward identifying effective treatments for neurological disorders such as Multiple Sclerosis. This divestiture is nonetheless sought after because the interested company is making a substantial offer for the HTDS subsidiary, which will fit will in the prospective purchaser's own portfolio.

The intended buyer of Slavica Biochem finds novel uses for currently marketed or near market drugs or therapeutic treatments. This company operates in a variety of market segments through the refinement and improvement of key parts of the value chain, and by enhancing company portfolios through strategic partnerships and in-licensing pharmaceuticals. Slavica technologies and methodology fit perfectly within the buyer's business realm, which is why the offer to purchase Slavica from HTDS is so lucrative.

The expected sale of Slavica Biochem, plus the soon to be announced divestiture of HTDS subsidiary Collagenna Skin Care Products, will allow HTDS to focus on its core business, China-based vaccine distributor Shenzhen Mellow Hope.